However, APOE ε4 dosage did not show significant modifying effects on the relationship of glucosamine use with incident vascular dementia (P for interaction = 0.188) and Alzheimer’s disease (P for interaction = 0.375). Here, APOE is linked to early-onset autosomal dominant Alzheimer disease.